Sarepta Theraps Inc Drug Patent Portfolio

Sarepta Theraps Inc's Family Patents


Family Patents



Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Sarepta Theraps Inc News

FDA Makes Announcement Regarding Replimune Following Developments from Sarepta and Soleno in the Biotechnology Industry

21 Aug, 2025

Pharmalittle: We're exploring Prasad's comeback at the FDA, a journal's conflict with RFK Jr., and additional updates.

11 Aug, 2025

Madrigal invests in GLP-1 through CSPC; Apellis receives broader drug approval.

31 Jul, 2025

Genzyme Files Lawsuit Against Sarepta Over Alleged Violation of Gene Therapy Patents

16 Aug, 2024

See More